Precipio Sees Q3 Revenue $4.5M Vs $4M Est.

-0.17%

Precipio, Inc.

PRPO

24.02

-0.17%

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.

The combination of ongoing revenue growth in both the pathology and products divisions, alongside efficiency and cost reduction initiatives has rapidly moved the company towards its goals.

"As we approach a $20M run rate, we expect our operating cash flow to approach breakeven. This year will mark a steep, but rewarding climb to get the company to where it can stand on its own feet financially," said Ilan Danieli, CEO.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.